165 related articles for article (PubMed ID: 8500224)
41. Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: a comparative study with clinically used platinum derivatives.
Feng Z; Lai Y; Ye H; Huang J; Xi XG; Wu Z
Cancer Sci; 2010 Nov; 101(11):2476-82. PubMed ID: 20813014
[TBL] [Abstract][Full Text] [Related]
42. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
43. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
44. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
45. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and antitumor activity of ammine/amine platinum(II) and (IV) complexes.
Khokhar AR; Deng Y; al-Baker S; Yoshida M; Siddik ZH
J Inorg Biochem; 1993 Aug; 51(3):677-87. PubMed ID: 8409984
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of in vitro cytotoxicity of 6-benzylaminopurine carboplatin derivatives against human cancer cell lines and primary human hepatocytes.
Dvořák Z; Starha P; Trávníček Z
Toxicol In Vitro; 2011 Apr; 25(3):652-6. PubMed ID: 21232594
[TBL] [Abstract][Full Text] [Related]
48. Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(II) complexes as new tumor targeting agents.
Gao X; Liu S; Shi Y; Huang Z; Mi Y; Mi Q; Yang J; Gao Q
Eur J Med Chem; 2017 Jan; 125():372-384. PubMed ID: 27688191
[TBL] [Abstract][Full Text] [Related]
49. Synthesis, antiproliferative activity and DNA binding study of mixed ammine/cyclohexylamine platinum(II) complexes with 1-(substituted benzyl) azetidine-3, 3-dicarboxylates.
Sun Y; Gou S; Yin R; Jiang P
Eur J Med Chem; 2011 Oct; 46(10):5146-53. PubMed ID: 21875765
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH
Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287
[TBL] [Abstract][Full Text] [Related]
51. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro.
Harstrick A; Casper J; Guba R; Wilke H; Poliwoda H; Schmoll HJ
Cancer; 1989 Mar; 63(6):1079-83. PubMed ID: 2645036
[TBL] [Abstract][Full Text] [Related]
52. The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.
Ormerod MG; Orr RM; O'Neill CF; Chwalinski T; Titley JC; Kelland LR; Harrap KR
Br J Cancer; 1996 Dec; 74(12):1935-43. PubMed ID: 8980393
[TBL] [Abstract][Full Text] [Related]
53. Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.
Theiner S; Varbanov HP; Galanski MS; Egger AE; Berger W; Heffeter P; Keppler BK
J Biol Inorg Chem; 2015 Jan; 20(1):89-99. PubMed ID: 25413442
[TBL] [Abstract][Full Text] [Related]
54. Cytotoxic activity of [Pt(pyr)(N-Etlm)Cl4].
Massacesi M; Matovic Z; Ponticelli G
Farmaco; 1993 Sep; 48(9):1327-30. PubMed ID: 8259989
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and oral antitumor activity of tetrakis(carboxylato)platinum(IV) complexes.
Lee YA; Lee SS; Kim KM; Lee CO; Sohn YS
J Med Chem; 2000 Apr; 43(7):1409-12. PubMed ID: 10753477
[TBL] [Abstract][Full Text] [Related]
56. Synthesis, biodistribution and antitumor activity of hematoporphyrin-platinum(II) conjugates.
Kim YS; Song R; Hyun Kim D; Jun MJ; Sohn YS
Bioorg Med Chem; 2003 Apr; 11(8):1753-60. PubMed ID: 12659761
[TBL] [Abstract][Full Text] [Related]
57. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
58. Synthesis, cytotoxicity and antitumor activity of platinum(II) complexes of cyclopentanecarboxylic acid hydrazide.
Kushev D; Gorneva G; Taxirov S; Spassovska N; Grancharov K
Biol Chem; 1999 Nov; 380(11):1287-94. PubMed ID: 10614821
[TBL] [Abstract][Full Text] [Related]
59. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
60. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
